The EPS projection of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for quarter ended 2016-09-30 is $-1.59. Last week, the projection for EPS was $-1.59 against target of $-1.59, a month earlier. While 2-months ago, this projection was $-1.59 versus forecast of $-1.59a quarter months earlier, posting a deviation of -0.01%.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 1 and 1. While in last 120 and 90 days, positive revisions were 1, and 1, correspondingly.
The per-share earnings downgrade for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the preceding 30 and 120 were 0 and 4. While in 60 and 90 days were 0, and 4, in that order.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EPS target was $-1.59 for the quarter closed 1. It was based on 9 calls. As on 2016-05-09 the EPS was $-1.35. The change was $-0.06, posting a deviation of -4.65%. The price projections gave a standard deviation of 0.15.
Quarterly Sales Estimates
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) sales prediction for the fiscal 2016 stands at $2.505 and the median estimate is at $2.505. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $4.49 while the lowest target is $0.52 showing standard deviation of 2.807%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of 0%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of 0%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...